Your browser doesn't support javascript.
loading
Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation.
Koyama, Nobuyuki; Iwai, Yuki; Nagai, Yoshiaki; Aoshiba, Kazutetsu; Nakamura, Hiroyuki.
Afiliación
  • Koyama N; Department of Clinical Oncology, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan.
  • Iwai Y; Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan.
  • Nagai Y; Department of Respiratory Medicine, Jichi Medical University, Tochigi, Japan.
  • Aoshiba K; Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan.
  • Nakamura H; Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan.
PLoS One ; 14(8): e0221718, 2019.
Article en En | MEDLINE | ID: mdl-31442290
OBJECTIVE: Lung cancer frequently co-exists with idiopathic interstitial pneumonia (IIP), which can be subdivided into idiopathic pulmonary fibrosis (IPF) and IIP other than IPF (other IIP). Although chemotherapy in small cell lung cancer (SCLC) patients with IIP may result in the exacerbation of IIP, these patients commonly receive chemotherapy. This study aimed to assess the risks and benefits of chemotherapy in SCLC patients with IIP. METHODS: We retrospectively analyzed the medical records of 122 patients with SCLC who received chemotherapy. Patients with secondary interstitial lung disease (ILD) of known etiology were excluded. Eligible patients were divided into two groups: SCLC with and without IIP. The former group was subdivided into those with IPF and other IIP. RESULTS: Of the 47 (39.2%) SCLC patients with IIP, 20 had IPF and 27 had other IIP. The frequency of chemotherapy-induced ILD development or IIP exacerbation was higher in patients with IPF (40.0%) than in those with other IIP (3.7%) and non-IIP (1.4%). Logistic regression analysis demonstrated that ILD development or IIP exacerbation was independently associated with IPF (P = 0.007). Time to treatment failure (P < 0.001) and overall survival (P = 0.001) were different among the groups., Cox proportional hazard model revealed that IPF was independently associated with time to treatment failure (P = 0,017) and overall survival (P = 0.006). Other IIP had no impact on time to treatment failure or overall survival. Development of ILD or exacerbation of IIP independently reduced time to treatment failure and overall survival. CONCLUSIONS: Comorbid IPF can be an independent, negative prognostic indicator and at high risk of ILD development or IIP exacerbation in SCLC patients. Early diagnosis and intervention for chemotherapy-induced IIP exacerbation will be beneficial for SCLC patients with IPF, who need close monitoring for its onset.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Progresión de la Enfermedad / Carcinoma Pulmonar de Células Pequeñas / Fibrosis Pulmonar Idiopática / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2019 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Progresión de la Enfermedad / Carcinoma Pulmonar de Células Pequeñas / Fibrosis Pulmonar Idiopática / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2019 Tipo del documento: Article País de afiliación: Japón